Press release from Companies
Publicerat: 2024-10-28 21:16:36
The shareholders of CS MEDICA A/S ("CS MEDICA" or the "Company") are hereby notified of an Extraordinary General Meeting to be held on Tuesday, 12 November 2024, at 15:00 via TEAMS.
Proposed Agenda
Ad 2: Further Details
For shareholders who currently hold fewer than 200 CS MEDICA shares or are just short of meeting a 200-share increment, there is the option to increase their holdings up until the EGM date to qualify for additional CANNORDIC shares in the distribution. A special announcement will follow this notice, providing all necessary information for shareholders regarding this distribution and the pre-IPO share purchase opportunity at a 20% discount. This ensures shareholders are fully informed and able to participate in both the distribution and the discounted share purchase.
The Issue costs related to the capital increases are expected to be approximately DKK 30.000.
The total number of votes as of the date of this notice is 13.805.305. The board has already received 8.700.630 positive votes, corresponding to 63%.
Registration
The registration date is 1 November 2024. Only shareholders registered on this date are entitled to participate and vote at the Extraordinary General Meeting.
Shareholders wishing to attend must request an admission card no later than 10 November 2024, at 11:59 PM CET. Requests should be made to Gitte Lund Henriksen at glh@cs-medica.com. Admission cards can also be requested for proxy holders under the same guidelines. Proxy and postal voting forms are available on the Company’s website and must be brought to the meeting by the proxy holder.
Participation
The Extraordinary General Meeting will be held on 12 November 2024, at 10:00 via TEAMS. Shareholders with shares registered in the name of a nominee must re-register their shares in their own names in the share register no later than 1 November 2024 to participate and vote.
Shareholders have the right to ask questions about agenda items, which can be submitted in writing before the meeting or asked during the meeting.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.